Singapore markets closed
  • Straits Times Index

    3,246.33
    -13.70 (-0.42%)
     
  • Nikkei

    26,717.34
    +547.04 (+2.09%)
     
  • Hang Seng

    23,550.08
    -256.92 (-1.08%)
     
  • FTSE 100

    7,466.07
    -88.24 (-1.17%)
     
  • BTC-USD

    38,133.35
    +1,132.34 (+3.06%)
     
  • CMC Crypto 200

    863.83
    +21.37 (+2.54%)
     
  • S&P 500

    4,431.85
    +105.34 (+2.43%)
     
  • Dow

    34,725.47
    +564.69 (+1.65%)
     
  • Nasdaq

    13,770.57
    +417.79 (+3.13%)
     
  • Gold

    1,792.30
    -2.70 (-0.15%)
     
  • Crude Oil

    87.29
    +0.68 (+0.79%)
     
  • 10-Yr Bond

    1.7820
    -0.0250 (-1.38%)
     
  • FTSE Bursa Malaysia

    1,520.02
    +4.03 (+0.27%)
     
  • Jakarta Composite Index

    6,645.51
    +34.35 (+0.52%)
     
  • PSE Index

    7,251.97
    -21.55 (-0.30%)
     

ACCUSTEM SCIENCES LIMITED (‘ACCUSTEM UK’) and ACCUSTEM SCIENCES INC (‘ACCUSTEM US’): Recommended corporate reorganisation by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006

·1-min read

SCHEME OF ARRANGEMENT EFFECTIVE

LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- ACCUSTEM UK is pleased to announce that, further to the announcement dated 30 November 2021 that the Court has sanctioned the Scheme, the Scheme Court Order has now been delivered to the Registrar of Companies and, accordingly, the recommended corporate reorganisation has now become effective in accordance with its terms.

Scheme Shareholders are entitled to receive 1 Share in Accustem US for every 20 Scheme Shares held.

Full details of the acquisition are set out in the Scheme Document published on 2 November 2021. Capitalised terms used but not otherwise defined in this announcement have the meaning given to them in the Scheme Document.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION

For further information please contact:

For further enquiries:
Accustem Sciences Limited
Gabriele Cerrone +44 (0)20 7495 2379


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting